Literature DB >> 6337396

Human insulin from recombinant DNA technology.

I S Johnson.   

Abstract

Human insulin produced by recombinant DNA technology is the first commercial health care product derived from this technology. Work on this product was initiated before there were federal guidelines for large-scale recombinant DNA work or commercial development of recombinant DNA products. The steps taken to facilitate acceptance of large-scale work and proof of the identity and safety of such a product are described. While basic studies in recombinant DNA technology will continue to have a profound impact on research in the life sciences, commercial applications may well be controlled by economic conditions and the availability of investment capital.

Entities:  

Mesh：

Substances：

Year:  1983        PMID： 6337396     DOI： 10.1126/science.6337396

Source DB:  PubMed          Journal:  Science        ISSN： 0036-8075            Impact factor:   47.728


  52 in total

1.  Expression, purification, and characterization of a dentin phosphoprotein produced by Escherichia coli, and its odontoblastic differentiation effects on human dental pulp cells.

Authors:  Ye-Rang Yun; Eunyi Jeon; Sujin Lee; Wonmo Kang; Sang-Gi Kim; Hae-Won Kim; Chang Kook Suh; Jun-Hyeog Jang
Journal:  Protein J       Date:  2012-08       Impact factor: 2.371

2.  Kernel energy method: application to insulin.

Authors:  Lulu Huang; Lou Massa; Jerome Karle
Journal:  Proc Natl Acad Sci U S A       Date:  2005-08-24       Impact factor: 11.205

Review 3.  Chlamydomonas reinhardtii: a protein expression system for pharmaceutical and biotechnological proteins.

Authors:  Christoph Griesbeck; Iris Kobl; Markus Heitzer
Journal:  Mol Biotechnol       Date:  2006-10       Impact factor: 2.695

Review 4.  The new biomedical technology.

Authors:  C H Scoggin
Journal:  West J Med       Date:  1985-12

Review 5.  Methods for Generating Hydrogel Particles for Protein Delivery.

Authors:  Allen L Liu; Andrés J García
Journal:  Ann Biomed Eng       Date:  2016-05-09       Impact factor: 3.934

Review 6.  Engineering biological systems toward a sustainable bioeconomy.

Authors:  Mateus Schreiner Garcez Lopes
Journal:  J Ind Microbiol Biotechnol       Date:  2015-04-07       Impact factor: 3.346

Review 7.  Trends in peptide drug discovery.

Authors:  Markus Muttenthaler; Glenn F King; David J Adams; Paul F Alewood
Journal:  Nat Rev Drug Discov       Date:  2021-02-03       Impact factor: 84.694

8.  Synthetic biology advances and applications in the biotechnology industry: a perspective.

Authors:  Leonard Katz; Yvonne Y Chen; Ramon Gonzalez; Todd C Peterson; Huimin Zhao; Richard H Baltz
Journal:  J Ind Microbiol Biotechnol       Date:  2018-06-18       Impact factor: 3.346

9.  Design-driven, multi-use research agendas to enable applied synthetic biology for global health.

Authors:  James M Carothers
Journal:  Syst Synth Biol       Date:  2013-07-20

Review 10.  The emergence of biosimilar insulin preparations--a cause for concern?

Authors:  David R Owens; Wolfgang Landgraf; Andrea Schmidt; Reinhard G Bretzel; Martin K Kuhlmann
Journal:  Diabetes Technol Ther       Date:  2012-10-09       Impact factor: 6.118
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.